{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:08:06Z","timestamp":1791623286713,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41401-024-01434-1","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T07:21:45Z","timestamp":1734333705000},"page":"1016-1029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hypocrellin A from an ethnic medicinal fungus protects against NLRP3-driven gout in mice by suppressing inflammasome activation"],"prefix":"10.1038","volume":"46","author":[{"given":"Le-jin","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao-li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei-lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-ping","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-song","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"1434_CR1","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397:1843\u201355.","journal-title":"Lancet"},{"key":"1434_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4078\/jrd.2022.0001","volume":"30","author":"JK Ahn","year":"2023","unstructured":"Ahn JK. Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean. J Rheum Dis. 2023;30:88\u201398.","journal-title":"J Rheum Dis"},{"key":"1434_CR3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380\u201390.","journal-title":"Nat Rev Rheumatol"},{"key":"1434_CR4","doi-asserted-by":"publisher","first-page":"e2226804","DOI":"10.1001\/jamanetworkopen.2022.26804","volume":"5","author":"N McCormick","year":"2022","unstructured":"McCormick N, Lu N, Yokose C, Joshi AD, Sheehy S, Rosenberg L, et al. Racial and sex disparities in gout prevalence among US adults. JAMA Netw Open. 2022;5:e2226804.","journal-title":"JAMA Netw Open"},{"key":"1434_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.861399","volume":"13","author":"JH Lee","year":"2022","unstructured":"Lee JH, Kim HS, Lee JH, Yang G, Kim HJ. Natural products as a novel therapeutic strategy for NLRP3 inflammasome-mediated gout. Front Pharmacol. 2022;13:861399.","journal-title":"Front Pharmacol"},{"key":"1434_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1434_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/bcp.12799","volume":"81","author":"DF Wright","year":"2016","unstructured":"Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016;81:277\u201389.","journal-title":"Br J Clin Pharmacol"},{"key":"1434_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4078\/jrd.2022.29.3.140","volume":"29","author":"SK Kim","year":"2022","unstructured":"Kim SK. The mechanism of the NLRP3 inflammasome activation and pathogenic implication in the pathogenesis of gout. J Rheum Dis. 2022;29:140\u201353.","journal-title":"J Rheum Dis"},{"key":"1434_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","volume":"13","author":"AK So","year":"2017","unstructured":"So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13:639\u201347.","journal-title":"Nat Rev Rheumatol"},{"key":"1434_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110466","volume":"121","author":"W Liu","year":"2023","unstructured":"Liu W, Peng J, Wu Y, Ye Z, Zong Z, Wu R, et al. Immune and inflammatory mechanisms and therapeutic targets of gout: An update. Int Immunopharmacol. 2023;121:110466.","journal-title":"Int Immunopharmacol"},{"key":"1434_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8274975","volume":"2020","author":"SM Silvestre","year":"2020","unstructured":"Silvestre SM, Almeida PJS, El-Shishtawy R. Natural products as a source for new leads in gout treatment. Evid Based Complement Altern Med. 2020;2020:8274975.","journal-title":"Evid Based Complement Altern Med."},{"key":"1434_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-023-03098-4","volume":"25","author":"N Schlesinger","year":"2023","unstructured":"Schlesinger N, Pillinger MH, Simon LS, Lipsky PE. Interleukin-1beta inhibitors for the management of acute gout flares: a systematic literature review. Arthritis Res Ther. 2023;25:128.","journal-title":"Arthritis Res Ther"},{"key":"1434_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","volume":"18","author":"S Paik","year":"2021","unstructured":"Paik S, Kim JK, Silwal P, Sasakawa C, Jo EK. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol. 2021;18:1141\u201360.","journal-title":"Cell Mol Immunol"},{"key":"1434_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/phar.1265","volume":"33","author":"TH Tran","year":"2013","unstructured":"Tran TH, Pham JT, Shafeeq H, Manigault KR, Arya V. Role of interleukin-1 inhibitors in the management of gout. Pharmacotherapy. 2013;33:744\u201353.","journal-title":"Pharmacotherapy"},{"key":"1434_CR15","first-page":"9169","volume":"24","author":"V Quagliariello","year":"2020","unstructured":"Quagliariello V, Bonelli A, Caronna A, Lombari MC, Conforti G, Libutti M, et al. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications? Eur Rev Med Pharmacol Sci. 2020;24:9169\u201371.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"1434_CR16","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","volume":"2","author":"V Kluck","year":"2020","unstructured":"Kluck V, Jansen T, Janssen M, Comarniceanu A, Efde M, Tengesdal IW, et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2020;2:e270\u201380.","journal-title":"Lancet Rheumatol"},{"key":"1434_CR17","doi-asserted-by":"publisher","first-page":"32145","DOI":"10.1073\/pnas.2009680117","volume":"117","author":"N Lonnemann","year":"2020","unstructured":"Lonnemann N, Hosseini S, Marchetti C, Skouras DB, Stefanoni D, D\u2019Alessandro A, et al. The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA. 2020;117:32145\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1434_CR18","doi-asserted-by":"publisher","first-page":"14447","DOI":"10.1021\/acs.jmedchem.3c01370","volume":"66","author":"N Li","year":"2023","unstructured":"Li N, Zhang R, Tang M, Zhao M, Jiang X, Cai X, et al. Recent progress and prospects of small molecules for NLRP3 inflammasome inhibition. J Med Chem. 2023;66:14447\u201373.","journal-title":"J Med Chem"},{"key":"1434_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","volume":"20","author":"AG Atanasov","year":"2021","unstructured":"Atanasov AG, Zotchev SB, Dirsch VM, International Natural Product Sciences T, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20:200\u201316.","journal-title":"Nat Rev Drug Discov"},{"key":"1434_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.895129","volume":"13","author":"Z Cheng","year":"2022","unstructured":"Cheng Z, Hu X, Lu X, Fang Q, Meng Y, Long C. Medicinal plants and fungi traditionally used by dulong people in Northwest Yunnan, China. Front Pharmacol. 2022;13:895129.","journal-title":"Front Pharmacol."},{"key":"1434_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/ja.2006.49","volume":"59","author":"LZ Fang","year":"2006","unstructured":"Fang LZ, Qing C, Shao HJ, Yang YD, Dong ZJ, Wang F, et al. Hypocrellin D, a cytotoxic fungal pigment from fruiting bodies of the ascomycete Shiraia bambusicola. J Antibiot (Tokyo). 2006;59:351\u20134.","journal-title":"J Antibiot (Tokyo)"},{"key":"1434_CR22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3389\/fphar.2017.00815","volume":"8","author":"X Lin","year":"2017","unstructured":"Lin X, Yan SZ, Qi SS, Xu Q, Han SS, Guo LY, et al. Transferrin-modified nanoparticles for photodynamic therapy enhance the antitumor efficacy of hypocrellin A. Front Pharmacol. 2017;8:815.","journal-title":"Front Pharmacol."},{"key":"1434_CR23","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1128\/AAC.48.11.4450-4452.2004","volume":"48","author":"G Ma","year":"2004","unstructured":"Ma G, Khan SI, Jacob MR, Tekwani BL, Li Z, Pasco DS, et al. Antimicrobial and antileishmanial activities of hypocrellins A and B. Antimicrob Agents Chemother. 2004;48:4450\u20132.","journal-title":"Antimicrob Agents Chemother"},{"key":"1434_CR24","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785\u201391.","journal-title":"J Comput Chem"},{"key":"1434_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04947-6","volume":"9","author":"H He","year":"2018","unstructured":"He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9:2550.","journal-title":"Nat Commun"},{"key":"1434_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","volume":"41","author":"Y He","year":"2016","unstructured":"He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41:1012\u201321.","journal-title":"Trends Biochem Sci"},{"key":"1434_CR27","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.immuni.2023.10.004","volume":"56","author":"R Miao","year":"2023","unstructured":"Miao R, Jiang C, Chang WY, Zhang H, An J, Ho F, et al. Gasdermin D permeabilization of mitochondrial inner and outer membranes accelerates and enhances pyroptosis. Immunity. 2023;56:2523\u201341.e8","journal-title":"Immunity"},{"key":"1434_CR28","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.celrep.2018.09.071","volume":"25","author":"JM Platnich","year":"2018","unstructured":"Platnich JM, Chung H, Lau A, Sandall CF, Bondzi-Simpson A, Chen HM, et al. Shiga toxin\/lipopolysaccharide activates caspase-4 and Gasdermin D to trigger mitochondrial reactive oxygen species upstream of the NLRP3 inflammasome. Cell Rep. 2018;25:1525\u201336.e7.","journal-title":"Cell Rep"},{"key":"1434_CR29","doi-asserted-by":"publisher","first-page":"15514","DOI":"10.1073\/pnas.1414859111","volume":"111","author":"J Yu","year":"2014","unstructured":"Yu J, Nagasu H, Murakami T, Hoang H, Broderick L, Hoffman HM, et al. Inflammasome activation leads to caspase-1-dependent mitochondrial damage and block of mitophagy. Proc Natl Acad Sci USA. 2014;111:15514\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1434_CR30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1142\/S0192415X03001624","volume":"31","author":"X Qu","year":"2003","unstructured":"Qu X, Dang L, Seale JP. Inhibitory effect of hypocrellin A on protein kinase C in liver and skeletal muscle of obese Zucker rats. Am J Chin Med. 2003;31:871\u20138.","journal-title":"Am J Chin Med"},{"key":"1434_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature09663","volume":"469","author":"R Zhou","year":"2011","unstructured":"Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221\u20135.","journal-title":"Nature"},{"key":"1434_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1413-8","volume":"10","author":"Y Yang","year":"2019","unstructured":"Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10:128.","journal-title":"Cell Death Dis"},{"key":"1434_CR33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","volume":"41","author":"J Fu","year":"2023","unstructured":"Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu Rev Immunol. 2023;41:301\u201316.","journal-title":"Annu Rev Immunol"},{"key":"1434_CR34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"P Broz","year":"2016","unstructured":"Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407\u201320.","journal-title":"Nat Rev Immunol"},{"key":"1434_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nature16959","volume":"530","author":"Y He","year":"2016","unstructured":"He Y, Zeng MY, Yang D, Motro B, Nunez G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature. 2016;530:354\u20137.","journal-title":"Nature"},{"key":"1434_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1074\/jbc.C115.700492","volume":"291","author":"JL Schmid-Burgk","year":"2016","unstructured":"Schmid-Burgk JL, Chauhan D, Schmidt T, Ebert TS, Reinhardt J, Endl E, et al. A genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation. J Biol Chem. 2016;291:103\u20139.","journal-title":"J Biol Chem"},{"key":"1434_CR37","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ni.3333","volume":"17","author":"H Shi","year":"2016","unstructured":"Shi H, Wang Y, Li X, Zhan X, Tang M, Fina M, et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol. 2016;17:250\u20138.","journal-title":"Nat Immunol"},{"key":"1434_CR38","doi-asserted-by":"publisher","first-page":"21984","DOI":"10.1073\/pnas.0910040106","volume":"106","author":"B Lomenick","year":"2009","unstructured":"Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, et al. Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci USA. 2009;106:21984\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1434_CR39","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41586-022-05570-8","volume":"613","author":"L Xiao","year":"2023","unstructured":"Xiao L, Magupalli VG, Wu H. Cryo-EM structures of the active NLRP3 inflammasome disc. Nature. 2023;613:595\u2013600.","journal-title":"Nature"},{"key":"1434_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237\u201341.","journal-title":"Nature"},{"key":"1434_CR41","doi-asserted-by":"publisher","first-page":"42073","DOI":"10.1039\/C7RA04748G","volume":"7","author":"L-Y Guo","year":"2017","unstructured":"Guo L-Y, Yan S-Z, Li Q, Xu Q, Lin X, Qi S-S, et al. Poly(lactic-co-glycolic) acid nanoparticles improve oral bioavailability of hypocrellin A in rat. RSC Adv. 2017;7:42073\u201382.","journal-title":"RSC Adv"},{"key":"1434_CR42","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ni.1935","volume":"11","author":"SL Masters","year":"2010","unstructured":"Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol. 2010;11:897\u2013904.","journal-title":"Nat Immunol"},{"key":"1434_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111442","volume":"138","author":"QL Chen","year":"2021","unstructured":"Chen QL, Yin HR, He QY, Wang Y. Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease. Biomed Pharmacother. 2021;138:111442.","journal-title":"Biomed Pharmacother"},{"key":"1434_CR44","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357\u201361.","journal-title":"Nature"},{"key":"1434_CR45","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature. 2013;493:674\u20138.","journal-title":"Nature"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01434-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T16:10:58Z","timestamp":1743351058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01434-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1038\/s41401-024-01434-1","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}